Kimberly‑Clark Offers EU Divestment Remedies as Kenvue Deal Nears Approval

Kimberly‑Clark has proposed divesting assets in Europe to address antitrust concerns and move closer to securing clearance from the European Union for its pending takeover of Kenvue. According to company filings and media reports from mid‑September, these proposed concessions are intended to mitigate regulatory hurdles as the roughly $40 billion transaction advances.

Recent regulatory filings indicate that Kimberly‑Clark is weighing the sale of certain brands in the EU as remedies to obtain antitrust approval. These measures are being pursued amid regulatory scrutiny over potential competition issues arising from the acquisition. The initiative reflects the company’s proactive strategy to fulfill the EU’s conditions and facilitate closing the deal within the second half of 2026.

Deal Status and Strategic Significance

The acquisition of Kenvue, announced in late 2025, aims to transform Kimberly‑Clark by adding a broad suite of consumer healthcare brands—such as Aveeno, Band‑Aid, Neutrogena and Tylenol—to its portfolio. Securing EU approval represents a critical regulatory milestone for the merger’s completion. Previous organizational adjustments—including a post‑closing leadership structure announced in April—anticipate the combined entity’s integration following regulatory clearance and customary closing conditions.

Implications for Investors

The proposed divestments signal a growing likelihood of deal approval in the EU, potentially paving the way for an imminent closing. For investors, this underscores the importance of monitoring formal decisions from EU regulators and any announcements regarding specific brands earmarked for sale. The ultimate scope and terms of the divestitures could influence Kimberly‑Clark’s long‑term revenue mix and strategic direction.

Next steps: the market will closely watch formal EU approval in the coming weeks or months, along with any confirmation of divestment terms. These developments will directly impact the timeline and structure of the combined Kimberly‑Clark and Kenvue entity.